Advertisement

PharmacoEconomics

, Volume 37, Issue 2, pp 267–278 | Cite as

Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand

  • Bunchai Chongmelaxme
  • Pochamana Phisalprapa
  • Ratree Sawangjit
  • Piyameth DilokthornsakulEmail author
  • Nathorn ChaiyakunaprukEmail author
Original Research Article

Abstract

Introduction

This study evaluated lifetime liver-related clinical outcomes, costs of treatment, and the cost-effectiveness of treatment options for non-alcoholic fatty liver disease (NAFLD) in Thailand.

Methods

A cost-utility analysis using a lifetime Markov model was conducted among Thai patients with NAFLD, from a societal perspective. Pioglitazone, vitamin E, a weight reduction program, and usual care were investigated, with the outcomes of interest being the number of cirrhosis and hepatocellular carcinoma (HCC) cases, life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and the incremental cost-effectiveness ratios (ICERs). One-way and probabilistic sensitivity analyses were performed.

Results

When compared with usual care, a weight reduction program can prevent cirrhosis and HCC cases by 13.91% (95% credible interval [CrI] 0.97, 20.59) and 2.12% (95% CrI 0.43, 4.56), respectively; pioglitazone can prevent cirrhosis and HCC cases by 9.30% (95% CrI −2.52, 15.24) and 1.42% (95% CrI −0.18, 3.74), respectively; and vitamin E can prevent cirrhosis and HCC cases by 7.32% (95% CrI −4.64, 15.56) and 1.12% (95% CrI −0.81, 3.44), respectively. Estimated incremental life expectancy and incremental QALYs for all treatment options compared with usual care were approximately 0.06 years and 0.07 QALYs, respectively. The lifetime costs of both a weight reduction program and pioglitazone were less than usual care, while vitamin E was $3050 (95% CrI 2354, 3650). The weight reduction program dominated all other treatment options. The probability of being cost-effective in Thailand’s willingness-to-pay threshold ($4546/QALY gained) was 76% for the weight reduction program, 22% for pioglitazone, 2% for usual care, and 0% for vitamin E.

Conclusions

A weight reduction program can prevent cirrhosis and HCC occurrences, and dominates all other treatment options. Pioglitazone and vitamin E demonstrated a trend towards decreasing the number of cirrhosis and HCC cases.

Notes

Acknowledgments

The authors wish to thank Peter Barton from the writing clinic at Naresuan University Language Center for editing this work.

Author Contributions

BC and PP participated in the study concept and design, data acquisition, data analysis, data interpretation, manuscript drafting, and critical revision and final review of the manuscript. RS, PD and NC participated in the study concept and design, data interpretation, manuscript drafting, and critical revision and final review of the manuscript.

Compliance with ethical standards

Conflicts of interest

Bunchai Chongmelaxme, Pochamana Phisalprapa, Ratree Sawangjit, Piyameth Dilokthornsakul, and Nathorn Chaiyakunapruk declare no potential conflicts of interest with respect to the research, organization, and publication of this work.

Financial support

The authors received no specific funding for this work.

Supplementary material

40273_2018_736_MOESM1_ESM.docx (194 kb)
Supplementary material 1 (DOCX 193 kb)

References

  1. 1.
    Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Hepatology. 2012;55:2005–23.CrossRefGoogle Scholar
  2. 2.
    Ashtari S, Pourhoseingholi MA, Zali MR. Non-alcohol fatty liver disease in Asia: prevention and planning. World J Hepatol. 2015;7:1788–96.CrossRefGoogle Scholar
  3. 3.
    Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011;9:428–33.CrossRefGoogle Scholar
  4. 4.
    Sayiner M, Otgonsuren M, Cable R, Younossi I, Afendy M, Golabi P, et al. Variables associated with inpatient and outpatient resource utilization among medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis. J Clin Gastroenterol. 2017;51:254–60.Google Scholar
  5. 5.
    Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21.CrossRefGoogle Scholar
  6. 6.
    Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–86.CrossRefGoogle Scholar
  7. 7.
    Summart U, Thinkhamrop B, Chamadol N, Khuntikeo N, Songthamwat M, Kim CS. Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: a population-based cross-sectional study. F1000Research. 2017;6:1630.Google Scholar
  8. 8.
    Phisalprapa P, Ujjin A, Apisarnthanarak P, Charoensak A, Washirasaksiri C, Srivanichakorn W, et al. Sa1050 Prevalence and risk factors of non-alcoholic fatty liver disease in asian individuals with metabolic syndrome. Gastroenterology. 2014;146:S-947.Google Scholar
  9. 9.
    EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59:1121–40.Google Scholar
  10. 10.
    Mahady SE, Wong G, Craig JC, George J. Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. Hepatology. 2012;56:2172–9.CrossRefGoogle Scholar
  11. 11.
    Sub-Committee of Thai Working Group on Health Technology Assessment. Thailand’s National Health Technology Assessment Guidelines. Nonthaburi: The Graphico Systems Co., Ltd.; 2009.Google Scholar
  12. 12.
    Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13:643–54.CrossRefGoogle Scholar
  13. 13.
    Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003;38:420–7.CrossRefGoogle Scholar
  14. 14.
    Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43:682–9.CrossRefGoogle Scholar
  15. 15.
    Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–8.CrossRefGoogle Scholar
  16. 16.
    Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485–93.CrossRefGoogle Scholar
  17. 17.
    Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24:248–54.CrossRefGoogle Scholar
  18. 18.
    Pachanee K, Wongphan T, Prakongsai P. Economic evaluation and budget impact analysis of liver transplantation among thai adults in universal health insurance coverage in Thailand. J Health Sci. 2016;25:908–19.Google Scholar
  19. 19.
    Subwongcharoen S, Treepongkaruna SA, Leelawat K, Ruksakul K. Long-term outcome of patients undergoing liver transplantation at Rajavithi Hospital, Thailand. J Med Assoc Thai. 2012;95:1292–6.Google Scholar
  20. 20.
    Poovorawan K, Treeprasertsuk S, Thepsuthammarat K, Wilairatana P, Kitsahawong B, Phaosawasdi K. The burden of cirrhosis and impact of universal coverage public health care system in Thailand: nationwide study. Ann Hepatol. 2015;14:862–8.CrossRefGoogle Scholar
  21. 21.
    Bureau of Non-communicable Diseases. Mortality rates of patients with non-communicable diseases in Thailand. Annaul report. 2015. http://thaincd.com/document/file/download/paper-manual/Annual-report-2015.pdf. Accessed 20 Dec 2017.
  22. 22.
    World Health Organization. Life tables: Thailand. 2013. http://apps.who.int/gho/data/node.country.country-THA?lang=en. Accessed 16 Nov 2016.
  23. 23.
    Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547–54.CrossRefGoogle Scholar
  24. 24.
    Leerapun A, Thaikruea L, Pisespongsa P, Chitapanarux T, Praisontarangkul OA, Thongsawat S. Clinical features and prognostic factors for liver cancer from a referral center in northern Thailand. J Med Assoc Thai. 2013;96:531–7.Google Scholar
  25. 25.
    Kositamongkol P, Sanphasitvong V, Sirivatanauksorn Y, Pongpaibul A, Limsrichamrern S, Mahawithitwong P, et al. Outcome of liver transplantation in hepatocellular carcinoma patients at Siriraj hospital. Transpl Proc. 2017;49:1114–7.CrossRefGoogle Scholar
  26. 26.
    Sirivatanauksorn Y, Kongkaewpaisan N, Pongpaibul A, Limsrichamrern S, Mahawithitwong P, Kositamongkol P, et al. Outcomes of orthotopic liver transplantation in non-malignant end-stage liver diseases. Transpl Proc. 2014;46:778–81.CrossRefGoogle Scholar
  27. 27.
    Sawangjit R, Chongmelaxme B, Phisalprapa P, Saokaew S, Thakkinstian A, Kowdley KV, et al. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a PRISMA-compliant systematic review and network meta-analysis. Medicine. 2016;95:e4529.CrossRefGoogle Scholar
  28. 28.
    Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol. 2001;96:579–83.CrossRefGoogle Scholar
  29. 29.
    Tongsiri S, Cairns J. Estimating population-based values for EQ-5D health states in Thailand. Value Health. 2011;14:1142–5.CrossRefGoogle Scholar
  30. 30.
    McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Making. 2008;28:582–92.CrossRefGoogle Scholar
  31. 31.
    Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008;11:527–38.CrossRefGoogle Scholar
  32. 32.
    Phisalprapa P, Supakankunti S, Charatcharoenwitthaya P, Apisarnthanarak P, Charoensak A, Washirasaksiri C, et al. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. Medicine. 2017;96(17):e6585.CrossRefGoogle Scholar
  33. 33.
    Riewpaiboon A. Standard cost list for health technology assessment. 2009. http://www.hitap.net/costingmenu/. Accessed 12 Dec 2016.
  34. 34.
    Drug and Medical Supply Information Center. Drug information service: Thailand. 2016. http://dmsic.moph.go.th/dmsic/index.php?&p=1&type=3&t=3&id=1. Accessed 16 Jul 2016.
  35. 35.
    Thongsawat S, Piratvisuth T, Pramoolsinsap C, Chutaputti A, Tanwandee T, Thongsuk D. Resource utilization and direct medical costs of chronic hepatitis C in Thailand: a heavy but manageable economic burden. Value Health Reg. 2014;3:12–8.CrossRefGoogle Scholar
  36. 36.
    Sub-committee of Thai Working Group on Health Technology Assessment. In: Meeting report of 2nd annual meeting. 2013.Google Scholar
  37. 37.
    Teerawattananon Y, Tritasavit N, Suchonwanich N, Kingkaew P. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. Z Evid Fortbild Qual Gesundhwes. 2014;108:397–404.CrossRefGoogle Scholar
  38. 38.
    Vemer P, Corro Ramos I, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. PharmacoEconomics. 2016;34(4):349–61.CrossRefGoogle Scholar
  39. 39.
    Phisalprapa P, Supakankunti S, Charatcharoenwitthaya P, Apisarnthanarak P, Charoensak A, Washirasaksiri C, et al. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. Medicine. 2017;96:e6585.CrossRefGoogle Scholar
  40. 40.
    Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885–904.CrossRefGoogle Scholar
  41. 41.
    Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367–78.CrossRefGoogle Scholar
  42. 42.
    Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176–84.CrossRefGoogle Scholar
  43. 43.
    Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–85.CrossRefGoogle Scholar
  44. 44.
    Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659–68.CrossRefGoogle Scholar
  45. 45.
    Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015;31:923–30.CrossRefGoogle Scholar
  46. 46.
    Xu R, Tao A, Zhang S, Deng Y, Chen G. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med. 2015;8:3924–34.Google Scholar
  47. 47.
    Filipova E, Uzunova K, Kalinov K, Vekov T. Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis. Diabetol Metab Syndr. 2017;9:90.CrossRefGoogle Scholar
  48. 48.
    Chen J, Jiang W, Shao L, Zhong D, Wu Y, Cai J. Association between intake of antioxidants and pancreatic cancer risk: a meta-analysis. Int J Food Sci Nutr. 2016;67(7):744–53.CrossRefGoogle Scholar
  49. 49.
    Chalasani N, Younossi Z. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57.CrossRefGoogle Scholar
  50. 50.
    Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep. 2013;13:329–41.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice, Faculty of Pharmaceutical SciencesNaresuan UniversityPhitsanulokThailand
  2. 2.Department of Medicine, Faculty of Medicine Siriraj HospitalMahidol UniversityBangkokThailand
  3. 3.Clinical Pharmacy Research Unit, Department of Clinical Pharmacy, Faculty of PharmacyMahasarakham UniversityMahasarakhamThailand
  4. 4.School of PharmacyMonash University MalaysiaSelangorMalaysia
  5. 5.School of PharmacyUniversity of WisconsinWisconsinUSA
  6. 6.Asian Centre for Evidence Synthesis in Population, Implementation and Clinical Outcomes (PICO), Health and Well-Being Cluster, Global Asia in the 21st Century (GA21) PlatformMonash University MalaysiaBandar SunwayMalaysia

Personalised recommendations